Holen Sie sich die Stockscreener-App
5.61
12.20%
0.61
Handel nachbörslich:
5.54
-0.07
-1.25%
Schlusskurs vom Vortag:
$5.00
Offen:
$5.06
24-Stunden-Volumen:
4.31M
Relative Volume:
4.97
Marktkapitalisierung:
$343.18M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-0.5655
EPS:
-9.92
Netto-Cashflow:
$-424.74M
1W Leistung:
+4.18%
1M Leistung:
+14.26%
6M Leistung:
-47.42%
1J Leistung:
-73.13%
1-Tages-Spanne:
$4.95
$5.62
1-Wochen-Bereich:
$4.94
$5.62
52-Wochen-Spanne:
$4.62
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
5.61 | 343.18M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-21 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Eingeleitet | Citigroup | Sell |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-04-17 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-08 | Herabstufung | Needham | Buy → Hold |
| 2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-03-31 | Eingeleitet | Berenberg | Hold |
| 2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-12-05 | Bestätigt | Guggenheim | Buy |
| 2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-23 | Eingeleitet | Wedbush | Outperform |
| 2019-04-25 | Eingeleitet | Jefferies | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
Postpartum Depression Therapeutics Market Size in the 7MM was ~USD 260 Million in 2023, is expected to grow by 2034, and estimates DelveInsight - The Globe and Mail
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Sage Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsSAGE - The Eastern Progress Online
Brokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $11.53 - MarketBeat
Sage Therapeutics price target lowered to $6 from $10 at Stifel - Yahoo Finance
Where Sage Therapeutics Stands With Analysts - Benzinga
Stifel Nicolaus Has Lowered Expectations for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Sage Therapeutics' SWOT analysis: navigating challenges in CNS drug stock - Investing.com
Sage Therapeutics' SWOT analysis: navigating challenges in CNS drug stock By Investing.com - Investing.com UK
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAGE - The Eastern Progress Online
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Sage Therapeutics shares stay Neutral rated by Mizuho, target cut on discontinued pipeline - Investing.com UK
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Fmr LLC - MarketBeat
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Eastern Progress Online
Investors who lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Eastern Progress Online
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for InvestorsContact The Gross Law Firm - The Eastern Progress Online
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders - The Eastern Progress Online
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
RTW Investments LP Buys 111,123 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
RBC Capital Upgrades Sage Therapeutics (SAGE) - MSN
Deutsche Bank Initiates Coverage of Sage Therapeutics (SAGE) with Hold Recommendation - MSN
Sage Therapeutics, Inc. Announces Retirement of Jeffrey M. Jonas as Member of Board of Directors , Effective December 1, 2024 - Marketscreener.com
Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Member of Board of Directors , Effective December 1, 2024 - Marketscreener.com
SAGE (Sage Therapeutics) Change In Inventory : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
SAGE (Sage Therapeutics) Cash Flow from Financing : $10.4 Mil (TTM As of Sep. 2024) - GuruFocus.com
Rx Rundown: Novartis, Sage Therapeutics, Eli Lilly and more - MM+M Online
Sage Therapeutics announces board member retirement By Investing.com - Investing.com Nigeria
Sage Therapeutics announces board member retirement - Investing.com India
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks By Investing.com - Investing.com South Africa
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace
Sage Therapeutics' SWOT analysis: stock faces hurdles amid CNS pipeline setbacks - Investing.com
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sage Therapeutics Inc-Aktie (SAGE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| IGUCHI KIMI | CFO & Treasurer |
Jan 02 '24 |
Option Exercise |
1.36 |
1,642 |
2,233 |
70,429 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):